A Phase I, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Single, Ascending Doses Of PF-05335810 In Hypercholesterolemic Subjects, With One, Open-Label, Multiple Fixed Dosage Cohort

Trial Profile

A Phase I, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Single, Ascending Doses Of PF-05335810 In Hypercholesterolemic Subjects, With One, Open-Label, Multiple Fixed Dosage Cohort

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Nov 2013

At a glance

  • Drugs Ralpancizumab (Primary) ; Ralpancizumab (Primary)
  • Indications Hypercholesterolaemia
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 01 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 13 May 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
    • 12 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top